Axitinib Shows Activity in Metastatic Renal Cell Carcinoma
Axitinib is effective in the first-line treatment of metastatic renal cell carcinoma, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
ASCO 2012
Regorafenib Ups Survival in mCRC After Standard Tx Failure
Regorafenib prolongs PFS and OS in metastatic colorectal cancer that has progressed after all approved standard therapies, according to the phase 3 CORRECT trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
T-DM1 Prolongs PFS in Some HER2+ Metastatic Breast Cancer Patients
The experimental agent trastuzumab emtansine (T-DM1) offers significant and “clinically meaningful” improvement in PFS in some patients with HER2+locally advanced or metastatic breast cancer, according to a phase 3 study prestented at the 2012 American Society of Clinical Oncology Annual Meeting.
Chemotherapy + Radiotherapy Ups Survival in Anaplastic Oligodendroglioma
Patients with anaplastic oligodendroglioma with co-deletion for chromosomes 1p and 19q survive significantly longer after receiving chemotherapy immediately prior to radiotherapy, according to long-term follow-up of a randomized phase 3 study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Patients with Lower Incomes Participate Less in Clinical Trials
Patients with annual household incomes below $50,000 vs over $50,000 were less likely to participate in clinical trials, according to results of a large national survey of people with cancer reported at the 2012 American Society of Clinical Oncology Annual Meeting.
OCEANS Confirms Bevacizumab Safety in Platinum-Sensitive Recurrent Ovarian Cancer
Updated safety data has confirmed the overall safety profile observed in patients with platinum-sensitive recurrent ovarian cancer in the randomized phase 3 OCEANS trial, according to a study reported during the 2012 American Society of Clinical Oncology Annual Meeting.
Cardiac Toxicity Unlikely with Adjuvant Sunitinib or Sorafenib in RCC
Follow-up data of patients with resected renal cell carcinoma and normal ejection fraction who received adjuvant sunitinib or sorafenib has led investigators to conclude neither agent is associated with significant cardiac dysfunction, according to a presentation at the 2012 American Society of Clinical Oncology Annual Meeting.
Pharmacogenetic Testing: Patients Willing to Pay, But Lack Understanding
Patients with cancer willing to undergo chemotherapy were also willing to pay for pharmacogenetic testing, even if it meant waiting 2 to 3 weeks for results, according to a study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Circulating Tumor Cells Correlated with Disease Stage in SCLC
Circulating tumor cells can be isolated and serially enumerated in patients with small cell lung cancer, and baseline CTCs can be directly correlated with disease stage, according to a report at the 2012 American Society of Clinical Oncology Annual Meeting.
No Benefit Seen with Erlotinib Maintenance Therapy in Ovarian Cancer
Maintenance erlotinib after first-line chemotherapy in ovarian cancer did not improve PFS or OS, according to results of a trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...